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Background: Thymidylate synthase (TS) is a key enzyme responsible for DNA synthesis and repair. Altered
expression of TS protein or TS gene polymorphisms has been associated with cancer progression and treatment
response. This study investigated the expressions of TS and its gene SNPs in non-small cell lung cancer (NSCLC),
and then its association with sensitivity to pemetrexed treatment. Immunohistochemistry and qRT-PCR were
performed on 160 resected NSCLC specimens and corresponding normal tissues to assess the expressions of TS
protein and TS mRNA, and for associations with clinicopathological data. Blood samples of 106 lung
adenocarcinoma patients were examined for polymorphisms of the TS gene 3’-UTR 1494del 6 bp, which was then
investigated for associations with responses of the patients to pemetrexed treatment and survival.
Results: Expression of both TS protein and its mRNA was elevated in NSCLC tissues compared with matched
normal tissues, and significantly higher in lung squamous cell carcinoma than in lung adenocarcinoma. TS
expression was associated with poor tumor differentiation. Furthermore, the genotyping data showed that 56% of
lung adenocarcinoma patients had the TS gene 3’-UTR 1494 bp (−6 bp/-6 bp) genotype and the rest had TS gene
3’-UTR 1494 bp (−6 bp/+6 bp). There was no TS 3’-UTR 1494 bp (+6 bp/+6 bp) genotype in any patients. Statistical
analysis revealed that gender, tumor stage, and TS 3’-UTR 1494del 6 bp polymorphism were significant prognostic
factors after short-term pemetrexed treatment. Log-rank analysis revealed that patients with the (−6 bp/-6 bp)
genotype had significantly better progression-free and overall survival than patients with (−6 bp/+6 bp).
Conclusions: This study showed that TS protein is highly expressed in NSCLC and that polymorphisms of TS 3’-UTR
1494del 6 bp are associated with sensitivity of lung adenocarcinoma patients to pemetrexed treatment. This
suggests that TS gene polymorphisms should be further evaluated as prognostic markers for personalized therapy
in lung adenocarcinoma.
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Lung cancer was the leading cause of cancer death in
men and the second leading cause in women worldwide
in 2008. Although lung cancer incidence is slowly de-
creasing in developed countries, the number of lung
cancer cases is still increasing in China and other devel-
oping countries [1]. Over 75% of all lung cancer cases
are NSCLC, which include adenocarcinoma, squamous
cell carcinoma, and large-cell carcinoma [2]. Common
treatments for NSCLC include surgery, chemotherapy,
radiation therapy, and palliative care depending on the
cancer type, stage, and other factors. Primary chemother-
apy is also given for advanced and metastatic NSCLC. A
combination of platinum chemotherapy compounds (cis-
platin or carboplatin) with gemcitabine, vinorelbine, or
taxanes (paclitaxel or docetaxel) is a widely used regimen
for first-line treatment of stage IIIB or IV NSCLC [2].
However, there is no standard regimen for local recur-
rence of NSCLC. In 2006, the National Comprehensive
Cancer Network recommended pemetrexed as a single
agent for second-line treatment of advanced NSCLC [3].
Pemetrexed is an antifolate drug that inhibits growth of
a variety of tumor types by targeting the folate-dependent
enzymes dihydrofolate reductase, glycinamide ribonucleo-
tide formyltransferase, and thymidylate synthase (TS); but
is most potent on TS [4,5]. To date, three large phase III
clinical trials have provided strong evidence for use of
pemetrexed in control of NSCLC [5-8]. The data also
showed that tumor histology was able to predict the sensi-
tivity of pemetrexed therapy in lung cancer, and that ex-
pression of TS mRNA and TS protein differed between
squamous cell lung cancer or NSCLC and lung adenocar-
cinoma [5]. However, patients with similar histotype and
disease stage might respond very differently to identical
treatments, which suggests that TS genotypes contribute
to these patients’ sensitivity to chemotherapeutic drugs.
Therefore, clinical studies have begun to focus on devel-
oping personalized treatments based on both histotype
and genotype to improve the efficacy of chemotherapy.
Indeed, it has been reported that the expression of TS
was induced in various cancers, including gastric, colorec-
tal, breast, and bladder cancers, compared with corre-
sponding normal tissues [6,7]. Functionally, TS generates
thymidine monophosphate (dTMP), which is subsequently
phosphorylated to thymidine triphosphate for use in DNA
synthesis and repair. TS is localized on chromosome 18,
covering 16 kb, and with 7 exons that translates into a
72-kD protein and functions as a homodimer. A previous
study showed that a 6-bp variation at 1494 bp of the TS
3'-UTR was associated with TS mRNA stability and
reduced TS protein expression [8]. Other studies showed
that this polymorphism also affected sensitivity to anti-
cancer drugs and prognoses of breast and gastrointestinal
cancers [6,9-11].In the present study, we first detected expression of
TS mRNA and TS protein in NSCLC tissue specimens,
and then determined the genotype at the TS 3'-UTR at
1494del in 106 lung adenocarcinoma patients to investi-
gate its association with sensitivity to pemetrexed.
Methods
Tissue specimens
A total of 160 chemotherapy-naive patients received
surgery at the Department of Thoracic Surgery, First
Affiliated Hospital of Liaoning Medical College between
January 2006 and March 2010. All tumors were con-
firmed histologically as adenocarcinoma or squamous
cell carcinoma of the lung. Representative fragments of
fresh tumor and adjacent normal-appearing lung tissue
were obtained and immediately snap frozen and stored
in liquid nitrogen until used. The remaining tissue was
fixed in formalin and embedded in paraffin. Our hospital
review board, the Ethics Committee of First Affiliated
Hospital of Liaoning Medical College, approved our
study, and each patient or their legal guardian signed a
consent form for participation in the study.
Semi-quantitative reverse-transcription (RT) PCR
Total RNA was extracted from tissue specimens using
Trizol (Tiangen Biotech, Beijing) in accordance with
the manufacturer’s instructions. cDNA was transcribed
from RNA samples using an iScript cDNA synthesis kit
(BioRad, Hercules, CA). Primers for amplification of TS
mRNA (NC_000018) were: 5’-TTGGACAGCCTGGGA
TTCTC-3’ (forward) and 5’-AGCTGGCGATGTTGAAA
GG-3’ (reverse). Primers for β-actin were 5’-GCATCC
ACGAAACTACCTT-3’ (forward) and 5’-CTCGTCATA
CTCCTGCTT-3’ (reverse), which were synthesized by
Aoke Biotech (Beijing). The PCR amplification was set
to 94°C for 2 min, then 35 cycles of 94°C for 45 s, 58°C
for 45 s, and 65°C for 90 s, and then 65°C for 10 min.
PCR products were separated in a 1.5% agarose gel by
electrophoresis at 90 V for one hour. β-actin mRNA was
the internal control.
For semi-quantitative PCR, we first tested different
cycles of PCR to amplify the TS mRNA (25–40 cycles)
and chose 35 cycles for our study. After PCR products
were resolved in a 1.5% gel, UV-light photos were taken
and the density of the bands was quantified using Gel-pro
Analyzer 4.5 software (Media Cybernetics, USA). The ex-
pression of TS mRNA was normalized as 47% of β-actin.
Immunohistochemistry
Tissue sections were prepared, deparaffinized, and rehy-
drated in accordance with standard protocols. Endogen-
ous peroxidase activity was quenched with 6% hydrogen
peroxide in methanol for 30 min. Antigen retrieval was
achieved by heating the tissue sections in a pressure
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nonspecific binding, the sections were incubated with
normal goat serum diluted in phosphate buffered saline
(PBS) for 30 min. After washing with PBS, the sections
were incubated with primary antibody overnight at 4°C fol-
lowed by a 30-min incubation with horseradish peroxidase-
conjugated secondary antibody at room temperature. The
monoclonal mouse anti-human antibody against thymidy-
late synthase and a PV-6000 immunohistochemistry kit
were purchased from Zhongshan (Beijing, China). The
sections were then incubated in a 3,3’-diaminobenzidine
chromogen solution and counterstained with Mayer’s
hematoxylin. Negative controls were prepared as above,
but without the primary antibody. Sections with known
TS expression served as the positive controls. The in-
tensity of TS expression was scored as 0, 1+, 2+, and 3+.
A score ≥2+ was classified as positive for TS.
Patients and treatment plan
One hundred and six patients were recruited from the
Department of Oncology, First Affiliated Hospital of
Liaoning Medical College between January 2006 and
March 2010. Of the 160 consecutive chemotherapy-naive
patients who received surgery at the Department of Thor-
acic Surgery, 119 cases were lung adenocarcinoma and 41
were lung squamous cell carcinoma. Thirteen patients
from the 119 lung adenocarcinomas were lost to follow-
up, resulting in 106 cases for data analysis.Figure 1 Detection of TS gene 3’-UTR 6 bp polymorphism at 1494 bp
to qPCR analysis of the TS gene polymorphism and then to DNA sequencin
1494 bp (−6 bp/-6 bp) and (−6 bp/+6 bp) polymorphisms. B and D, DNA s
and (−6 bp/+6 bp).The patients were histologically or cytologically con-
firmed as stage IIIB or IV lung adenocarcinoma and
subjected to pemetrexed treatment. The patients had
adequate organ functions and an Eastern Cooperative
Oncology Group (ECOG) performance status of 0, 1, or
2. The hospital’s ethics review board approved the study
protocol for pemetrexed therapy and all patients signed
written informed consent before treatment.
Prior to pemetrexed infusion, the patients took 4 mg
dexamethasone orally twice a day for three days. The
patients also took 400 μg folic acid once a day, begin-
ning 7 days before pemetrexed infusion and for 21 days
after the final treatment. In addition, the patients were
injected (intravenous) with 1000 μg vitamin B12 on the
day before the first pemetrexed treatment and then once
every three cycles of pemetrexed administration there-
after. The patients were given 500 μg/m2 pemetrexed
through a single intravenous infusion that lasted more
than 10 min, repeated once every 3 weeks.
Before entering the study, these patients underwent a
physical examination and tumor measurement with
computed tomography (CT) or magnetic resonance im-
aging (MRI). Overall survival (OS) after pemetrexed use
was measured from the first date of pemetrexed therapy
to the date of death or the last follow-up. A perspective
clinical follow-up, including chest CT scan and tele-
phone inquiry, was performed for all patients. Follow-
up time was calculated from the end of chemotherapy. Genomic DNA was extracted from blood from patients and subjected
g analysis. A and C, qPCR amplification curves show TS 3’-UTR
equencing data on TS 3’-UTR 1494 bp (−6 bp/-6 bp)
Table 1 Association of TS protein expression with
clinicopathological data from patients with NSCLC






< 60 72 45 63 1.1 0.29
≥ 60 88 62 70
Gender
Male 84 51 61 3.0 0.08
Female 76 56 74
Disease stage
IIIB 108 75 69 1.0 0.32
IV 52 32 62
ECOG grade
0 48 28 58 2.4 0.31
1 74 53 72




41 34 83 6.4 0.01
Adenocarcinoma 119 73 61
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of the study in June 2011. Disease status was assessed
according to the Response Evaluation Criteria in Solid
Tumors [12]. Complete response (CR) or partial re-
sponse (PR) was considered evidence of short-term ef-
fective treatment. A treatment that resulted in stable
disease (SD) or progressive disease (PD) was judged in-
effective. Long-term efficacy analysis included evalua-
tions of OS and progression-free survival (PFS). PFS
was defined as the time from the first date of peme-
trexed therapy to the date of documented progression
or death from any cause.
Quantitative PCR (qPCR) detection of the TS gene 3’-UTR
polymorphism
Genomic DNA was extracted from peripheral blood of
the patients using the AxyPrep Mag Blood Genomic
DNA kit (Axygen, Union City, CA) in accordance with
the manufacturer’s instructions. To detect the TS gene
3’-UTR polymorphism at 1494 bp, the fragment con-




TTAAAGA-MGB-3’), and rs34489327-CR (5’-HEX-AT
GAACTTTATAGTTGTT-MGB-3’) (AllGlo™). The PCR
program was set at 95°C for 5 min, and then 45 cycles
of 95°C 10 s and 55°C 40 s using a Rotor-Gene 3000 A
(Corbett Research, Australia). Representative qPCR re-
action curves of the TS 3’-UTR 1494 genotypes
(−6 bp/-6 bp) and (−6 bp/+6 bp) are shown in
Figure 1A and C. Three randomly selected PCR pro-
ducts from each genotype were subjected to DNA
sequence analysis for confirmation of the TS 3’-UTR
alterations.
Statistical analyses
All statistical analyses were performed using SPSS 17.0
software (SPSS, Chicago, IL). For the assessing the asso-
ciation of TS expression with clinicopathological fea-
tures, the probability (P) value was calculated using the
chi-squared (χ2) test. TS mRNA expression is shown as
mean ± standard deviation.
Grade correspondence analysis was performed using
the non-parametric Spearman’s rank correlation coeffi-
cient. Expressions of TS mRNA and TS protein was
analyzed with McNemmar and Spearman’s tests. The
Kaplan-Meier method was used to estimate PFS and
OS. Survival rates were compared with the log-rank test.
Multivariate analysis of the independent prognostic fac-
tor for survival was performed using the Cox propor-
tional hazard regression model with a 95% confidence
interval (CI). A 5% or lower P-value was considered
statistically significant.Results
Increased expression of TS mRNA and TS protein in
NSCLC
In this study, we first collected 160 clinically annotat-
ed NSCLC samples and corresponding normal tissues
between January 2006 and March 2010. The baseline
patient and disease-related characteristics are shown in
Table 1.
TS mRNA was expressed in 73.13% (117/160) of
NSCLC samples and 66.25% (92/160) of the normal tissue
samples (Figure 2), a difference that is statistically signifi-
cant (χ2 =8.621, P = 0.003). Moreover, levels of TS mRNA
were significantly higher in lung squamous cell carcinoma
than in lung adenocarcinoma (0.71 ± 0.18 compared with
0.21 ± 0.23, P < 0.05).
TS protein was expressed in 66.88% (107/160) of
NSCLC tissues, which was significantly higher than that
of normal tissues (57.5%, 79/160; χ2 = 10.066, P = 0.002).
TS protein was mainly expressed in the nuclei, with
some in the cytoplasm (Figure 3). In addition, 83% of
lung squamous cell carcinoma showed positive TS stain-
ing, which was significantly higher than that of lung
adenocarcinoma (61%; P = 0.01).
We then investigated the association between the
expression of TS protein and the patients’ clinicopatho-
logical characteristics. We found that expression of TS
protein was significantly associated with tumor histology
(P < 0.05), but did not associate with other clinical fea-
tures such as age, gender, disease stage, or ECOG grade
(P > 0.05; Table 1). Expression of TS mRNA was positively
Figure 2 Elevated expression of TS mRNA in NSCLC tissue
specimens compared to normal tissues. Surgical specimens were
taken from patients with lung adenocarcinoma (A) or squamous cell
carcinoma (S) and the corresponding normal mucosae (N) and
subjected to semi-quantitative RT-PCR analysis of TS expression. The
data are summarized as mean ± standard deviation relative to β-
actin. The size of TS and β-actin PCR products was 337 bp and
500 bp, respectively. S (0.712 ± 0.183) compared with A
(0.712 ± 0.183), P < 0.05.
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test (r = 0.861, P = 0.000).
TS gene 3’-UTR 6 bp polymorphism at 1494del associated
with clinical outcome of NSCLC patients after pemetrexed
treatment
We treated 106 patients with stage IIIB or IV lung adeno-
carcinoma for up to 6 cycles of pemetrexed (Table 2). The
efficacy of pemetrexed treatment was assessed for all 106
patients.
Blood samples were collected from each patient and
genotyped for the TS gene 3’-UTR polymorphism at
1494del 6 bp (Figure 1A and C). We found two genotypesFigure 3 Enhanced expression of TS protein in NSCLC compared with
with NSCLC were prepared and stained with anti-TS antibody and then rev
medium, and high levels of TS expression, respectively. D, Negative staining
squamous cell carcinoma. F, low level of TS expression in lung adenocarcinof 3’-UTR 1494 bp in these patients, -6 bp/-6 bp and
-6 bp/+6 bp. Three samples of each genotype were sub-
jected to DNA sequencing for confirmation of the poly-
morphisms (Figure 1B and D). The data showed that
55.7% (59/106) of patients were (−6 bp/-6 bp), 44% (47/
106) were (−6 bp/+6 bp), and 0% (0/106) were (+6 bp/
+6 bp). The allelic distribution was in Hardy-Weinberg
equilibrium (χ2 = 6.6, P = 0.83).
We then determined the association of these poly-
morphisms and clinicopathological data with sensitivity
to pemetrexed, and short- and long-term efficacy of
pemetrexed treatment, based on Response Evaluation
Criteria in Solid Tumors (RECIST). Statistical analysis
showed that gender, tumor stage, and the polymorphism
of the TS 3’-UTR 1494del 6 bp were all prognostic
factors for short-term efficacy of pemetrexed treatment
(P < 0.05, Table 2). Of the (−6 bp/-6 bp) patients, 32%
displayed a positive short-term response, whereas the
responses of 13% of the (−6 bp/+6 bp) patients were
also favorable. Furthermore, logistic regression analysis
revealed that the difference in short-term efficacy be-
tween these 2 genotypes was statistically significant
(P = 0.008), indicating that the TS 3’-UTR 1494del 6 bp
polymorphism is an important prognostic predicator.
The Kaplan-Meier curves (Figure 4) revealed that after
treatment with pemetrexed, the median PFSs of (−6 bp/-
6 bp) and (−6 bp/+6 bp) patients were 3.4 and 2.9 months,
respectively. Log-rank analysis revealed that patients with
(−6 bp/-6 bp) had significantly better PFS than patients
with (−6 bp/+6 bp) (χ2 = 12, P = 0.0010, Figure 4A). More-
over, the median OS of (−6 bp/-6 bp) and (−6 bp/+6 bp)
patients were 14 and 12 months, respectively. Statistical
analysis showed a significantly better OS for patients withthe corresponding normal tissues. Paraffin sections from patients
iewed and scored under a microscope. A-C, Representative low,
of normal tissues. E, strong expression of TS protein in lung
oma.
Table 2 Association of pemetrexed treatment responses
with clinicopathological data from lung adenocarcinoma
patients
No. of patients Efficacy χ2 P value
CR + PR
Age (years)
< 60 50 16 3.7 0.06
≥ 60 56 9
Gender
Male 62 10 4.6 0.03
Female 44 15
Disease stage
IIIB 78 24 5.6 0.02
IV 28 1
ECOG grade




−6 bp/-6 bp 59 19 5.5 0.02
−6 bp/+6 bp 47 6
Expression of TS protein
TS(+) 67 11 5.1 0.02
TS(−) 39 14
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Cox regression analysis showed that age, tumor stage, the
type of polymorphism, and expression of TS protein of
the TS 3’-UTR 1494del 6 bp significantly affected the OS
of patients (P < 0.05), whereas gender and the ECOG score
did not influence the survival significantly (Table 3).Figure 4 Kaplan-Meier analysis of survival in lung
adenocarcinoma and TS 3’-UTR 6 bp 1494del polymorphisms.
Kaplan-Meier plot of progression-free survival (PFS, A) and overall
survival (OS, B) of the patients by genotypes (−6 bp/-6 bp) (blue
line, n = 59) or (−6 bp/+6 bp) (green line, n = 47).Association between adverse drug reactions and TS gene
3'-UTR 1494 bp
Adverse drug reactions of these patients to pemetrexed
treatment were defined in accordance with the National
Cancer Institute Common Toxicity Criteria (NCI-CTC)
version 3.0 [13]. The most frequently occurring adverse
drug reaction was bone-marrow inhibition, followed by
gastroenterological discomfort and liver and kidney
damage. However, no patients withdrew from treatment
due to adverse drug reactions. Patients with the -6 bp/-
6 bp genotype had more adverse drug reactions to the
drug treatment than -6 bp/+6 bp patients, but the differ-
ence was not statistically significant (Table 4). Overall,
the patients tolerated and complied with this drug treat-
ment, making pemetrexed useful for controlling tumor
progression and improving the quality of life of these
advanced lung cancer patients.Discussion
Our current study showed that TS is highly expressed in
NSCLC and that polymorphisms of TS 3’-UTR 1494del
6 bp are associated with lung adenocarcinoma patients’
sensitivity to pemetrexed treatment. Otake et al. [14]
was the first to show TS overexpression in NSCLC, i.e.,
60.9% of 23 resected NSCLC samples displayed TS pro-
tein expression. Furthermore, they also performed the
fluorodeoxyuridine-5'-monophosphate binding assay and
found that TS enzymatic activity ranged from 1.8 to 56.9
pmol/g protein in NSCLC samples, indicating that TS
may be involved in NSCLC tumorigenesis [14]. Nakagawa
Table 3 Multivariate analysis of patients’ survival







Wald P Exp (b) 95% CI
Gender −0.31 0.22 2.0 0.16 0.73 0.48-1.1
Age 0.61 0.22 7.5 0.01 1.8 2.0-2.8
Tumor stage 0.77 0.24 11 0.00 2.1 1.4-3.5
ECOG grade −0.27 0.16 2.8 0.10 0.80 0.55-1.1




−0.60 0.28 4.6 0.03 0.55 0.32-1.0
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associated with increased levels of TS expression, espe-
cially in lung adenocarcinoma cells. Our current study
showing upregulated expression of TS mRNA and TS in
NSCLC tissue specimens compared with normal tissues,
confirmed the data of Otake et al. [14] and Nakagawa
et al. [15]. The upregulated levels of TS expression in
squamous cell lung carcinoma were associated with poor
tumor differentiation, which is consistent with a study
reported by Ceppi et al. [16].
However, Hashimoto et al. [17] showed that expres-
sion of TS mRNA was associated with lymph node me-
tastasis, clinical stage, and tumor cell proliferation of
lung adenocarcinoma. Although the data of the presentTable 4 Association between the adverse drug reactions
and TS gene 3'-UTR 1494 bp
Grade Genotype (n = cases) χ2 P
−/− (n = 59) −/+ (n = 47)
Leukopenia I, II 22 16 0.057 0.483
III, IV 0 1 1.241 0.449
Neutropenia I, II 21 19 0.117 0.437
III, IV 0 0 - -
Thrombocytopenia I, II 10 11 0.457 0.330
III, IV 0 0 - -
Nausea, Vomiting I, II 9 10 0.447 0.337
III, IV 0 1 1.241 0.449
Diarrhea I, II 11 9 0.003 0.573
III, IV 0 0 - -
Constipation I, II 14 10 0.057 0.498
III, IV 0 0 - -
Fatigue I, II 15 10 0.155 0.435
III, IV 0 0 - -
Renal damage I, II 0 0 - -
III, IV 0 0 - -
Liver damage I, II 2 1 0.143 0.590
III, IVstudy showed that TS expression in patients with lymph
node metastasis and stage IIIA was higher than that of
patients without lymph node metastasis and with stage I
or II, the difference did not reach statistical significance.
Polymorphisms of the TS gene have been reported to
correlate with clinical outcomes of chemotherapy. For
example, Mandola et al. [10] showed that the TS 3’-UTR
1494del 6 bp polymorphism was correlated with low TS
expression in colorectal cancer. Dotor et al. [9] reported
that colon cancer patients with TS 3’-UTR 1494del 6 bp
exhibited better response to 5-FU-based adjuvant ther-
apy. A previous Chinese study [18] reported a similar re-
sult, i.e., TS 3’-UTR 1494del 6 bp was correlated with
sensitivity to chemotherapy in advanced gastric cancer
patients. However, another study reported that there was
no association between this polymorphism and clinical
outcome after chemotherapy [7]. These data indicate
that polymorphisms of TS 3’-UTR 1494del 6 bp may be
related to the response to particular chemotherapy agents
or with different types of cancer. In our current study, we
found an association between TS 3’-UTR 1494del 6 bp
polymorphisms and outcome of pemetrexed treatments in
lung adenocarcinoma patients.
A previous study reported that the +6 bp/1494 dele-
tion polymorphism was more frequent in Caucasians
(Los Angeles, CA), while the -6 bp/1494 was dominant
in Chinese (Singapore) [10]. Gao et al. [19] found that
Chinese patients with gastric cancer had 44.8% (−6 bp/-
6 bp), 44.3% (−6 bp/+6 bp), and 7.6% (+6 bp/+6 bp) TS
gene polymorphisms. In the present study, the short-
term response to pemetrexed treatment was 32.20% and
12.77% in (−6 bp/-6 bp) and (−6 bp/+6 bp) patients,
respectively, indicating that patients with the (−6 bp/-
6 bp) polymorphism had a better response rate to peme-
trexed treatment than those with the (−6 bp/+6 bp)
polymorphism (HR: 4.382; 95% CI: 1.462 to 13.130;
P = 0.008). A recent clinical trial of stage III NSCLC
patients (known as the JMDB trial) with pemetrexed in
combination with cisplatin found that the overall re-
sponse rate was 27.1% [20]. While the current study
supports the effectiveness of pemetrexed for NSCLC
patients, the JMDB study did not include an analysis of
TS gene 3’-UTR 1494 bp polymorphisms.
The current study found that the PFS and OS between
patients with (−6 bp/-6 bp) and (−6 bp/+6 bp) were sig-
nificantly different. The multivariate analysis showed that
older age, advanced disease stage, and the TS 3’-UTR
1494 bp (−6 bp/+6 bp) genotype were prognostic for a
poorer outcome. However, these data need to be con-
firmed in a large perspective clinical trial. In addition, with
our current data it was not possible to analyze the associ-
ation between the TS polymorphisms (−6 bp/-6 bp) and
(−6 bp/+6 bp) and induced expression of TS in the
NSCLC tissues available to us in this study. This is
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from pemetrexed-treated patients. Fortunately, a previous
study did mechanistically demonstrate the link between
them [21].
Conclusions
This study showed that TS protein is highly expressed in
NSCLC and that polymorphisms of TS 3’-UTR 1494del
6 bp are associated with sensitivity of lung adenocarci-
noma patients to pemetrexed treatment. Our study sug-
gests that TS gene polymorphisms should be further
evaluated as prognostic markers for personalized chemo-
therapy in lung adenocarcinoma.
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